Key result
Circulating MDA-LDL levels were significantly associated with the presence of thin-cap fibroatheromas (OR 1.45 per 10-unit increment; 95% CI 1.24-1.68; P<0.001).
Why the study?
Are circulating MDA-LDL levels associated with the presence of thin-cap fibroatheromas in patients with coronary artery disease?
Cross-Sectional (n=102)
Are circulating MDA-LDL levels associated with the presence of thin-cap fibroatheromas in patients with coronary artery disease?
Odds Ratio: 1.45 (95% CI 1.24–1.68)
p-value: p=< 0.001
Circulating MDA-LDL levels are significantly associated with the presence of vulnerable plaques (TCFAs) in patients with coronary artery disease.
AIMS: The importance of oxidized low-density lipoprotein (oxLDL) has been implicated in the process of plaque rupture. However, few previous studies demonstrated the relationship between plaque morphology and oxLDL. We evaluated the relationship between coronary plaque vulnerability assessed by optical coherence tomography (OCT) and circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL). METHODS AND RESULTS: OCT was used to determine plaque vulnerability in 102 patients with acute coronary syndrome (ACS; n = 53) and stable angina pectoris (SAP; n = 49). Circulating levels of MDA-LDL were measured by using enzyme-linked immunosorbent assay. Thin-cap fibroatheromas (TCFAs; defined as lipid-rich with plaque cap thickness <65 μm) were detected more frequently in ACS than in SAP (83% vs. 16%, P < 0.001). The circulating levels of MDA-LDL were significantly higher in patients with ACS compared with SAP (P = 0.008). The levels of MDA-LDL were significantly higher in SAP patients with TCFA than those with non-TCFA (P < 0.001). Although the levels of MDA-LDL were not significant between ACS patients with TCFA and those with non-TCFA, patients with ruptured TCFA had higher levels of MDA-LDL compared with those with morphologically intact TCFA (P = 0.023). MDA-LDL levels were associated with the presence of TCFA (odds ratio, 1.45 per 10-unit increment of MDA-LDL; 95% CI, 1.24-1.68; P< 0.001) in multivariable logistic regression analysis. CONCLUSION: Circulating MDA-LDL levels might be associated with the presence of TCFA in the culprit lesion.
No takes yet. Share an insight, caveat, or question.
Matsuo et al. (2012) conducted a cross-sectional in Coronary artery disease (n=102). Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) was evaluated on Presence of thin-cap fibroatheromas (TCFAs) (OR 1.45, 95% CI 1.24-1.68, p=< 0.001). Circulating MDA-LDL levels were significantly associated with the presence of thin-cap fibroatheromas (OR 1.45 per 10-unit increment; 95% CI 1.24-1.68; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: